ADARX PHARMACEUTICALS TARGETS $1.74B VALUATION IN U.S. IPO RNA drug developer ADARx Pharmaceuticals plans to sell 21.875M shares at $15-$17 each, raising up to $371.9M and valuing the company at as much as $1.74B. AbbVie will separately purchase about 5.01M shares in a concurrent private placement, giving it roughly a 4.9% stake after the IPO. ADARx is developing next-generation siRNA drugs, with five wholly owned programs spanning hereditary angioedema, complement diseases, stroke prevention, obesity and neurodegenerative diseases. Its most advanced drug, onvuzosiran, is currently in Phase 3 for hereditary angioedema, with topline data expected by the end of 2027. The FDA granted the program Fast Track status in August. At the $16 midpoint, ADARx expects roughly $397M in combined net proceeds from the IPO and AbbVie placement, with the largest allocations planned for: • $180M for agazisiran and its complement-disease programs • $80M for stroke candidate ADX-626 • $65M for Phase 3 onvuzosiran • $25M for obesity program ADX-077 • $20M for neurodegeneration program ADX-199 The company says the proceeds, together with existing cash and investments, should fund operations into 2030. ADARx plans to list on Nasdaq under $ADRX. Source: SEC filing, Reuters

🚨Chelsea have received interest from Benfica for Tosin Adarabioyo. It would reunite him with former Fulham manager Marco Silva. There is also interest from at least one other Premier League club. He has less than two years left on his contract.

#GenZSpeaks# | What are young people in Keralam talking about? Hear directly from student leaders Ann Sebastian (KSU), R Aswathy (ABVP) and @Adarshmsaji (SFI). #IndiaTodayKeralamRoundTable# #Promo#